AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA/INOCA Patients: A Prospective, Multicenter, Single-Group Target Value Study

Recruitingn/aAges 18 Years - anyAllPeking University Third Hospital
💬

In plain words

What the trial is, and whether it could suit you

This study aims to evaluate the sensitivity and specificity of a multi-sensor wireless pressure microcatheter for the diagnosis of CMD in patients with ANOCA/INOCA, using quantitative myocardial perfusion imaging of cardiac magnetic resonance (CMR) as a reference.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age ≥ 18 years, gender not limited; 2. Symptoms of angina pectoris, or objective evidence of myocardial ischemia (e.g., electrocardiogram, myocardial injury markers, etc.); 3. Visual assessment of coronary angiography shows diameter stenosis \< 50% and FFR \> 0.8 (or cRR \> 0.89); 4. Microvascular function assessment is planned; 5. Agree to participate in this clinical study and voluntarily sign the informed consent form. Exclusion Criteria: 1. Acute myocardial infarction, PCI, CABG, or valvular surgery following angiography within the past 30 days; 2. Severe valvular disease requiring surgical or interventional treatment; 3. Chest pain with known non-ischemic causes (e.g., pericarditis, pulmonary hypertension, esophageal spasm); 4. Contraindications to CMR (e.g., certain types of pacemakers or defibrillators, severe claustrophobia); 5. Clear contraindications to adenosine and ATP use (e.g., second- or third-degree atrioventricular block, sick sinus syndrome, severe asthma, systolic blood pressure below 90 mmHg); 6. Renal insufficiency (eGFR ≤ 45 mL/min/1.73 m2) or currently undergoing dialysis; 7. Severe heart failure or LVEF ≤ 35%; 8. Severe organ disease or life expectancy less than 2 years; 9. Known to be participating in other drug or device clinical trials that have not yet met the primary endpoint; 10. Other investigators deem the candidate unsuitable for this clinical trial.
💊

What it tests

  • Not listed
📍

Where

5 sites
Wang Jing Hospital Of CACMS(China Academy of Chinese Medical Sciences)
Beijing, China
Cangzhou Central Hospital
Cangzhou, China
Chengdu Second People's Hospital
Chengdu, China
Beijing Anzhen Hospital.Capital Medical University
Beijing, China
Peking University Third Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy